Savant Capital LLC Trims Holdings in DaVita Inc. (NYSE:DVA)

Savant Capital LLC lessened its stake in DaVita Inc. (NYSE:DVA) by 3.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,695 shares of the company’s stock after selling 145 shares during the period. Savant Capital LLC’s holdings in DaVita were worth $387,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in DVA. Robeco Institutional Asset Management B.V. raised its stake in shares of DaVita by 175.4% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 50,343 shares of the company’s stock valued at $4,759,000 after purchasing an additional 32,062 shares in the last quarter. IFM Investors Pty Ltd lifted its holdings in DaVita by 78.1% during the 3rd quarter. IFM Investors Pty Ltd now owns 21,115 shares of the company’s stock worth $1,996,000 after buying an additional 9,261 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of DaVita by 19.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,369 shares of the company’s stock worth $1,642,000 after acquiring an additional 2,790 shares in the last quarter. Park Avenue Securities LLC bought a new stake in shares of DaVita in the 3rd quarter valued at approximately $332,000. Finally, CENTRAL TRUST Co lifted its stake in DaVita by 93.3% during the third quarter. CENTRAL TRUST Co now owns 1,448 shares of the company’s stock worth $137,000 after purchasing an additional 699 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DaVita

In other news, insider James O. Hearty sold 26,164 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the transaction, the insider now directly owns 20,264 shares in the company, valued at $2,424,384.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Javier Rodriguez sold 67,603 shares of DaVita stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the transaction, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider James O. Hearty sold 26,164 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the sale, the insider now directly owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The disclosure for this sale can be found here. Insiders sold 134,540 shares of company stock worth $16,551,071 in the last 90 days. Corporate insiders own 1.40% of the company’s stock.

Analyst Upgrades and Downgrades

DVA has been the topic of a number of research reports. Truist Financial increased their target price on shares of DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a report on Tuesday, February 20th. Barclays assumed coverage on DaVita in a report on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 target price for the company. UBS Group raised their price target on DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. StockNews.com upgraded DaVita from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 25th. Finally, TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $118.50.

DaVita Stock Performance

Shares of NYSE DVA opened at $134.45 on Monday. DaVita Inc. has a 12-month low of $71.51 and a 12-month high of $145.04. The company has a current ratio of 1.43, a quick ratio of 1.37 and a debt-to-equity ratio of 7.95. The company has a market cap of $11.79 billion, a PE ratio of 15.28, a P/E/G ratio of 1.17 and a beta of 1.04. The stock has a 50 day simple moving average of $133.71 and a 200-day simple moving average of $112.84.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.95 by $0.43. The company had revenue of $3.07 billion during the quarter, compared to analyst estimates of $3.03 billion. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The firm’s quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.58 EPS. On average, equities research analysts forecast that DaVita Inc. will post 9.49 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.